trials will be delayed for regulatory or other reasons; and risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activiti'/>/>SOURCE Neurocrine Biosciences, Inc.Copyright??2010 PR Newswire.All rights reserved0GOODPage: 1 2 3 4 5 6 Related medicine technology :1.